Stelios brings more than four decades of experience in the biopharmaceutical industry in various roles: as a company founder, executive, investment banker, and leader in the global healthcare sector.
In addition to his role as our co-founder and Chairman, Stelios is Chairman of the Board of Directors of Exelixis, Inc., and a member of the board of Graviton Biosciences Corp and Ovid Therapeutics, Inc. He is a co-founder of Exelixis, as well as former Chairman of Regulus Therapeutics (acquired by Novartis in 2025), and co-founder and former Chairman of Anadys Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and Cellzome (acquired by GlaxoSmithKline in 2012). Until recently he was the Chairman of Biogen, having joined that board in 2008. In the not-for-profit sector, Stelios is co-founder and Chairman of Fondation Santé, a foundation providing research support and mentorship to biomedical scientists in Greece and Cyprus.
Stelios spent six years (2000-06) at Cowen & Co., LLC, most recently as Vice Chairman, where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where he was an analyst in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette. Stelios has received multiple honors and awards for his work in the biopharma industry as a company founder, adviser, and financier.
Before coming to Wall Street, Stelios was in the faculty of the Department of Cell Biology at New York University School of Medicine. Stelios holds an MS in physics, a PhD in biophysics, and an MBA in finance, all from New York University.